DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents.

Author(s): Abdel-Rahman SM, Kearns GL, Topelberg S, Jacobs RF, Mistry GC, Majumdar A, Xu Y, Wagner JA, Kitchen CJ, Groff M, Herman G, Blumer JL

Affiliation(s): Division of Pediatric Clinical Pharmacology and Medical Toxicology, The Children's Mercy Hospital, Kansas City, MO, USA.

Publication date & source: 2010-12, Pediatr Infect Dis J., 29(12):1072-6.

Publication type: Multicenter Study; Research Support, N.I.H., Extramural

BACKGROUND: Ertapenem is a carbapenem antibiotic with broad spectrum activity and a pharmacokinetic profile that favors once-daily administration in adults. OBJECTIVES: This investigation was designed to evaluate the dose-exposure profile of ertapenem in children from infancy through adolescence. METHODS: Eighty-four children (3 months-16 years) requiring antibiotic therapy were enrolled in this multicenter trial. Children received a single intravenous dose of ertapenem at 15, 20, or 40 mg/kg followed by repeated blood sampling for 24 hours. Free and total plasma ertapenem concentrations were quantitated by high-performance liquid chromatography, and the pharmacokinetics were determined using a model-independent approach. RESULTS: Ertapenem exposure increased proportionally with increasing dose; however, achievable concentrations were influenced by age. Children older than 12 years attained higher dose-normalized concentrations at the end of the infusion (concentration at the end of the infusion [Ceoi]: 8.7 +/- 1.9 mg/L per mg/kg dose) and total body exposure (area under the curve area under the plasma concentration-time curve [AUC]0-infinity: 34.7 +/- 14.7 mg hr/L per mg/kg dose) as compared with children 2 to 12 years (Ceoi: 6.9 +/- 2.4 mg/L per mg/kg dose, AUC0-infinity: 18.4 +/- 8.0 mg hr/L per mg/kg dose) and children younger than 2 years (Ceoi: 6.1 +/- 2.2 mg/L per mg/kg dose, AUC0-infinity: 17.0 +/- 5.4 mg hr/L per mg/kg dose). These findings were accounted for by age-dependent changes in ertapenem clearance and distribution volume. In 3 children adverse events (nausea, n = 2; injection site reaction, n = 1) were considered related to study drug administration. CONCLUSIONS: Children younger than 12 years require dosing more frequently than once daily to achieve optimal efficacy when treating organisms with a minimum inhibitory concentration near the susceptibility breakpoint.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017